阿尔金因:一种潜在的预防性补充剂对 transthyretin amyloidosis 的治疗
Atsushi Fukunari1, Hiroaki Matsushita1, Tamon Furukawa1
1Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University, Huis Ten Bosch, Sasebo, Nagasaki, Japan.
氨酸稳定了跨氨酸 (TTR) 四基,防止了TTR氨基粉症 (ATTR) 中的错误折叠和粉样纤维的形成. 这种常见的氨基酸补充剂对ATTR预防有前途.
科学领域:
- 生物化学 生物化学
- 蛋白质错折叠疾病 蛋白质错折叠疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 晶氨酸 (TTR) 四聚合物解离成单聚物驱动TTR氨基粉症 (ATTR) 病原体.
- 目前的TTR稳定剂成本昂贵,不适合用于预防.
- 需要新的预防策略来延迟ATTR进展.
研究的目的:
- 调查阿金宁作为一种潜在的预防性补充剂,防止TTR粉样蛋白形成.
- 为了确定阿尔金宁是否能稳定TTR四基体,从而抑制氨基基生成.
主要方法:
- 在体外和人体血清中进行免疫血清测试,以评估TTR四聚/单聚的比例.
- 提奥夫拉T测定量化粉样纤维的形成.
- 通过口服给健康志愿者服用阿金宁.
主要成果:
- 氨酸显著增加了TTRwt,ATTR V30M和人类血清样本中的TTR四聚/单聚比.
- 在健康个体中,口服阿基尼因的使用提高了血清TTR四聚/单聚的比率.
- 与对照组相比,氨酸明显抑制了粉样蛋白纤维的形成.
结论:
- 氨酸有效地稳定了TTR四度体,抑制了粉样纤维的形成.
- 氨酸显示出作为ATTR的安全和可访问的预防补充剂的潜力.
- 对阿尔金因在TTR氨基粉症中的治疗作用进行进一步的研究是有必要的.
更多相关视频
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Alzheimer's Disease: Treatment
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Rheumatic Heart Disease III: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
